Announced additional excellent results from the finished initial cohort of an ongoing Phase 2a.

Ardea Biosciences reports outcomes of RDEA594 Stage 2a study for hyperuricemia and gout pain Ardea Biosciences, Inc special type . announced additional excellent results from the finished initial cohort of an ongoing Phase 2a, proof-of-concept research of RDEA594, its business lead product candidate for the treating hyperuricemia and gout. All patients receiving RDEA594 experienced a dose-related reduction in uric acid amounts in their blood. Patients who excrete significantly less than normal quantities of uric acid make up around 90 percent of the gout patient population and are the primary focus on for treatment with RDEA594. A majority of individuals randomized to RDEA594 also had mild to moderate renal impairment at baseline and 86 percent of these patients responded to RDEA594 at two weeks.

Comments are closed.